ArticleJournal of neuroinflammation2026
Sex specific effects of adoptive Tregs transfer on the brain and periphery in maternal immune activation offspring rescuing immune dysregulation.
Article in Journal of neuroinflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07521371 (Observational Study of Intranasal Insulin Delivery in Autism Spectrum Disorder Ages 4 to 21 Years), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Observational Study of Intranasal Insulin Delivery in Autism Spectrum Disorder Ages 4 to 21 Years (INS-AUT)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autism spectrum disorder (ASD) is characterized by atypical communication, social interactions, and restricted interests. In ASD, there are dysfunctional immune regulatory control mechanisms that can lead to immune activation. Notably lower frequencies of regulatory T cells (Tregs) and reduced immunosuppressive cytokines are reported and associated with more impaired behaviors impacting both individuals with autism and their families. Therefore, therapeutic approaches that enhance immune regulation may offer substantial benefits. Using the maternal immune activation (MIA) model, we investigated whether adoptive transfer of wildtype Tregs into MIA offspring recipients could rescue immune activation, brain transcriptome changes and behaviors exhibited in adult MIA offspring. We also aimed to explore potential sex-differences in responses. In male but not female MIA offspring, Tregs transfer reduced the frequency of T helper (TH)-17 (RORγT⁺ CD4⁺) T cells in both the mesenteric lymph node (MLN) and spleen. Moreover, the frequency of CD25⁺Foxp3⁺ T cells was increased in the MLN and spleen of male but not female MIA offspring following Tregs transfer. Splenocytes from male MIA offspring receiving Tregs showed reduced production of inflammatory cytokines (e.g., IL-6 and TNFα) following PMA/Ionomycin stimulations. In contrast, female MIA offspring that received Tregs exhibited different cytokine profiles characterized by increased production of cytokines, including GM-CSF, IFNγ, and IL-10. In the brain, bulk mRNA sequencing in the cerebellum, frontal cortex, and hippocampus revealed that Tregs-treated male MIA offspring had differentially expressed genes involved in neurodevelopmental disorders, synaptic function, and epigenetic regulation. Minimal gene expression differences were observed in female counterparts. There was significant improvement in self-grooming behaviors in males MIA offspring that received Tregs. In females, social novelty improved after Tregs treatment. In summary, adoptive Tregs transfer reduced systemic inflammation, brain transcription and behavior alterations in a sex dependent manner in the context of MIA. These findings suggest that adoptive Tregs transfer may represent a viable therapeutic avenue for mitigating systemic inflammation and comorbidities associated with MIA and neurodevelopmental disorders such as ASD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.